CIN No.: L24230TG1995PLC020093



## CONCORD DRUGS LIMITED

Admn. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail: concorddrugsltd@gmail.com Website: www.concorddrugs.in

To,

Date: 27.04.2021

BSE Limited P.J. Towers, Dalal Street Mumbai-400001

Dear Sir/ Madam,

Sub: Disclosure under Regulation 40(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

With reference to the subject cited, please find enclosed the disclosure u/r 40 (9) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the half year ended 31.03.2021.

Thanking you.

Yours sincerely, For Concord Drugs Limited

S. Nagi Reddy

Chairman & Whole time Director

DIN: 01764665

Encl. as above



## CERTIFICATE UNDER REGULATION 40 (9) OF THE SEBI (LODR) REGULATIONS, 2015 FOR THE HALF YEAR ENDED 31.03.2021

I have examined all Share Transfer forms, Memorandum of Transfers, Registers, files and other documents relating to CONCORD DRUGS LIMITED, maintained by AARTHI CONSULTANTS PRIVATE LIMITED, pertaining to transfer of equity shares of the company for the period from 01.10.2020 to 31.03.2021 for the purpose of issuing a Certificate as per Regulation 40(9) of the SEBI (LO&DR) Regulations, 2015, by CONCORD DRUGS LIMITED and based on the information provided by the Company, I hereby certify that there was no case for lodgement for physical transfer, subdivision, consolidation, renewal, exchange of share certificate(s) or endorsement of calls/allotment monies for the period 01.10.2020 to 31.03.2021 and therefore no share certificate was issued.

For Vivek Surana & Associates

Place: Hyderabad Date: 27.04.2021

UDIN: A024531C000190301

Vivek Surana Proprietor

M. No. A24531, C.P. No. 12901

CP.NO